| . | Obese BMI (≥30) . | Overweight BMI (25 to <30) . | Normal BMI (18.5 to <25) . | Underweight BMI (<18.5) . | P . |
|---|---|---|---|---|---|
| Overall (n = 254) | 55.3% (21 of 38) | 45.1% (32 of 71) | 51.3% (60 of 117) | 67.9% (19 of 28) | 0.890 |
| Q8 wk (n = 131) | 58.8% (10 of 17) | 52.4% (22 of 42) | 50.0% (31 of 62) | 70.0% (7 of 10) | 0.884 |
| Q12 wk (n = 123) | 52.4% (11 of 21) | 34.5% (10 of 29) | 52.7% (29 of 55) | 66.7% (12 of 18) | 0.919 |
| TNF antagonist naïve (n = 206) | 56.7% (17 of 30) | 45.8% (27 of 59) | 53.7% (51 of 95) | 76.0% (19 of 25) | 0.423 |
| Prior TNF antagonist (n = 48) | 50.0% (4 of 8) | 38.5% (5 of 13) | 61.9% (13 of 21) | 0% (0 of 3) | 0.088 |
| . | Obese BMI (≥30) . | Overweight BMI (25 to <30) . | Normal BMI (18.5 to <25) . | Underweight BMI (<18.5) . | P . |
|---|---|---|---|---|---|
| Overall (n = 254) | 55.3% (21 of 38) | 45.1% (32 of 71) | 51.3% (60 of 117) | 67.9% (19 of 28) | 0.890 |
| Q8 wk (n = 131) | 58.8% (10 of 17) | 52.4% (22 of 42) | 50.0% (31 of 62) | 70.0% (7 of 10) | 0.884 |
| Q12 wk (n = 123) | 52.4% (11 of 21) | 34.5% (10 of 29) | 52.7% (29 of 55) | 66.7% (12 of 18) | 0.919 |
| TNF antagonist naïve (n = 206) | 56.7% (17 of 30) | 45.8% (27 of 59) | 53.7% (51 of 95) | 76.0% (19 of 25) | 0.423 |
| Prior TNF antagonist (n = 48) | 50.0% (4 of 8) | 38.5% (5 of 13) | 61.9% (13 of 21) | 0% (0 of 3) | 0.088 |
| . | Obese BMI (≥30) . | Overweight BMI (25 to <30) . | Normal BMI (18.5 to <25) . | Underweight BMI (<18.5) . | P . |
|---|---|---|---|---|---|
| Overall (n = 254) | 55.3% (21 of 38) | 45.1% (32 of 71) | 51.3% (60 of 117) | 67.9% (19 of 28) | 0.890 |
| Q8 wk (n = 131) | 58.8% (10 of 17) | 52.4% (22 of 42) | 50.0% (31 of 62) | 70.0% (7 of 10) | 0.884 |
| Q12 wk (n = 123) | 52.4% (11 of 21) | 34.5% (10 of 29) | 52.7% (29 of 55) | 66.7% (12 of 18) | 0.919 |
| TNF antagonist naïve (n = 206) | 56.7% (17 of 30) | 45.8% (27 of 59) | 53.7% (51 of 95) | 76.0% (19 of 25) | 0.423 |
| Prior TNF antagonist (n = 48) | 50.0% (4 of 8) | 38.5% (5 of 13) | 61.9% (13 of 21) | 0% (0 of 3) | 0.088 |
| . | Obese BMI (≥30) . | Overweight BMI (25 to <30) . | Normal BMI (18.5 to <25) . | Underweight BMI (<18.5) . | P . |
|---|---|---|---|---|---|
| Overall (n = 254) | 55.3% (21 of 38) | 45.1% (32 of 71) | 51.3% (60 of 117) | 67.9% (19 of 28) | 0.890 |
| Q8 wk (n = 131) | 58.8% (10 of 17) | 52.4% (22 of 42) | 50.0% (31 of 62) | 70.0% (7 of 10) | 0.884 |
| Q12 wk (n = 123) | 52.4% (11 of 21) | 34.5% (10 of 29) | 52.7% (29 of 55) | 66.7% (12 of 18) | 0.919 |
| TNF antagonist naïve (n = 206) | 56.7% (17 of 30) | 45.8% (27 of 59) | 53.7% (51 of 95) | 76.0% (19 of 25) | 0.423 |
| Prior TNF antagonist (n = 48) | 50.0% (4 of 8) | 38.5% (5 of 13) | 61.9% (13 of 21) | 0% (0 of 3) | 0.088 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
